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Abstract
Background: Herpes viruses establish a life-long latency and can cause symptoms during both first-time infection
and later reactivation. The aim of the present study was to describe the seroepidemiology of Herpes simplex type
1 (HSV1), Herpes simplex type 2 (HSV2), Cytomegalovirus (CMV), Varicella Zoster virus (VZV) and Human herpes virus
type 6 (HHV6) in an adult Swedish population (35–95 years of age).
Methods: Presence of antibodies against the respective viruses in serum from individuals in the Betula study was
determined with an enzyme-linked immunosorbent assay (ELISA). Singular samples from 535 persons (53.9%
women, mean age at inclusion 62.7 ± 14.4 years) collected 2003-2005 were analyzed for the five HHVs mentioned
above. In addition, samples including follow-up samples collected 1988–2010 from 3,444 persons were analyzed
for HSV.
Results: Prevalence of HSV1 was 79.4%, HSV2 12.9%, CMV 83.2%, VZV 97.9%, and HHV6 97.5%. Herpes virus infections
were more common among women (p = 0.010) and a lower age-adjusted HSV seroprevalence was found in later birth
cohorts (p < 0.001). The yearly incidence of HSV infection was estimated at 14.0/1000.
Conclusion: Women are more often seropositive for HHV, especially HSV2. Age-adjusted seroprevalence for HSV was
lower in later birth cohorts indicating a decreasing childhood and adolescent risk of infection.
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Introduction
Human herpesviruses (HHV1-8) are ubiquitous human
pathogens with a global distribution. Epidemiological
studies have identified geographic location, socioeconomic
status, and age as primary factors for acquisition of HHV
infection [1]. The infection cycle involves a primary infec-
tion, followed by a latency phase that may be interrupted
by episodes of reactivated infection [1]. Although this pat-
tern of infection is shared by all HHVs, variation among
the included viral species exists e.g. concerning the tissue
involved in the latency phase of the infection. HHV1-3
(HSV1, HSV2 and VZV) establish latency in sensory gan-
glia, while the other HHVs (EBV, CMV, HHV6-8) employ
lymphocytes, monocytes, and sometimes also epithelium
for latency. When reactivated, HHV1-3 spread along
nerves, HHV4 (EBV), HHV7 and HHV8 expand in
lymphocyte populations, while HHV5 (CMV) and HHV6
often spread systemically [1]. HHVs have been attributed a
role in the development of chronic disorders, such as
Alzheimer’s disease [2–6], cardiovascular disease [7–9],
cognitive impairment [10, 11], and depression [12–14].
We, and others researching the field of late neurological
sequela from HHV infections have had great use of
serological screening in cohorts of adult and elderly indi-
viduals [5, 6, 15–18]. Although literature on the seroepide-
miology of HHV infections is extensive, most studies
focus on young individuals or selected populations posing
already known risks from HHV infections [19–22]. We
therefore performed the present study with the aim to
estimate the prevalence of HHV1 (HSV1), HHV2 (HSV2),
HHV3 (VZV), HHV5 (CMV), and HHV6 in serum
samples retrieved from individuals in the Betula study
[23], reflecting a population of adults, including the eld-
erly, in Sweden. For HSV1&2 combined, we further ana-
lyzed a larger cohort with longitudinal samples allowing
for estimation on the trend in yearly incidence.* Correspondence: jan.l.olsson@umu.se1Department of Clinical Microbiology, Virology, Umeå University, Umeå,
Sweden
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Methods
Participants
The Betula study is an ongoing longitudinal, prospective
cohort study with the overall aim of investigating how
memory function and health develop across the adult life
span [23]. The study is designed as a mixed cohort and
cross-sectional study, modeled after Schaie [24, 25], to
enable the separation of age, cohort and time of meas-
urement effects.
The Betula study started in 1988 by recruiting 1,000
persons from the municipality of Umeå – a municipality
of about 120,000 inhabitants located in Northern
Sweden. The participants were randomly selected
from the Swedish Population Registry, and were in-
vited to participate via an introductory letter and a
follow-up telephone call. Recruitment continued until
participants within all age groups were fully enrolled.
In the first wave, 1,976 persons were contacted to ob-
tain 1,000 participants. To fulfill the primary study
aims, persons with severe visual or auditory deficits,
cognitive deficits due to intellectual disability, severe
psychiatric illness, suspected dementia, and those who
did not speak and understand the Swedish language
were excluded.
The first cohort (sample 1; S1) of 1,000 persons was
investigated in 1988 – 1990 (time-point 1; T1), and was
followed-up every five years thereafter until 2008 –
2010 (T2 to T5). Additional cohorts, from the same
geographical region were included at each subsequent
wave of investigation (T2 to T5). At T2 (1993 – 1995)
two cohorts (S2, n = 997, and S3, n = 966) were enrolled,
at T3 (1998 – 2000) one cohort of 563 persons (S4), and
T4 (2003 – 2005) another cohort of 562 persons (S5) was
enrolled.
S1 and S2 comprised persons aged 35, 40, 45, 50, 55,
60, 65, 70, 75 and 80 years at inclusion, with up to 100
individuals in each age group. The S3 cohort comprised
persons aged 40 to 85 at inclusion, up to 100 in each age
group, and the S4 and S5 cohorts comprised people in
12 different age groups from 35 to 95 years old at inclu-
sion, with up to 50 in each group. The proportion of
men and women in each cohort and age group was
equal, roughly corresponding to the gender distribution
in the general population.
The S3 cohort, like S1, was followed with repeated
examinations every five years until T5. A part of the S2
cohort was re-examined at T3 but not thereafter,
whereas S4 (1998 – 2000) and S5 (2004 – 2006) were
examined only at the time of inclusion.
Samples included for the cross-sectional analysis of
anti-HSV1, anti-HSV2, anti-VZV, anti-CMV and anti-
HHV6 were all stored serum samples available from S5T4
(n = 535, age 35-95, sampling timepoint 2003-2005). One
sub-cohort, sampled once, was selected from the Betula
study to make assessment of the five HHVs sero-
prevalence affordable, and this particular cohort (S5T4)
was found suitable because its samples are relatively
recent, and it contains participants of a wide age-
distribution. Samples included in the additional cross-
sectional and longitudinal analysis of anti-HSV were all
stored serum samples available from S1-5 T1-5. The
total number of participants was 3,444, from which
2,213 contributed one sample, and 1,231 provided two
or more samples from different sampling timepoints
(1988 – 1990, 1993 – 1995, 1998 – 2000, 2003 – 2005,
and 2008 – 2010).
Serum analyses
Frozen serum samples were thawed and analyzed for
anti-HSV, anti-VZV, anti-CMV, and anti-HHV6 IgG
antibodies using Enzyme-linked immunosorbent assays
(ELISA). In a procedure to separate anti-HSV positive
samples into anti-HSV1, anti-HSV2, or anti-HSV1 + 2
positive, anti- HSV positive samples were further ana-
lyzed for presence of anti-HSV2 IgG, afterwhich anti-
HSV2 positive samples were analyzed for presence of
anti-HSV1 IgG. For anti-HSV, anti-VZV, and anti-CMV,
ELISA assays developed in-house were used [26–28],
for anti-HSV1 and anti-HSV2 HerpeSelect®-assays
(Focus diagnostics) were utilised, and for anti-HHV6
the HHV-6 IgG Antibody ELISA Kit (Advanced bio-
technologies inc.) was used. For the in-house methods,
antigens against HSV, VZV, and CMV were acquired
by growth of HSV1 Umeå clinical isolate 3458-13 on
GMK cells, VZV strain SMI 1197 on VeroE6 cells, and
CMV strain Ad169 on HumB cells, respectively. Plasma
incubation on antigen-coated ELISA plates was performed
at 4 °C overnight. Analyses were performed in duplicate
using uninfected cell extract as a negative control. In each
ELISA run, high and low positive controls and a negative
control were included to monitor the quality of individual
runs and inter-assay variation. Plasma were diluted 1/420
in phosphate buffered saline supplemented with 0.05%
(v/v) Tween-20 and 1% dried milk. IgG antibodies were
identified using goat F(ab)2 anti-human IgG, alkaline
phosphatase conjugate (Invitrogen) diluted 1/6000, and
developed using p-nitrophenyl phosphate disodium
substrate (Sigma-Aldrich). The IgG antibody activity of
the individual sample was expressed in arbitrary units
(AU) as a percentage of the net-absorbance at 405 nm
(absorbance of virus-coated well minus absorbance of
control antigen well) of the positive control. Samples
with IgG values of 5 AU or above were regarded as
positive for HHV IgG antibody content.
All serological methods were run according to routine
analyses performed in the clinical diagnostics lab, which
is a part of Norrlands Universitetssjukhus (NUS). The
Olsson et al. Immunity & Ageing  (2017) 14:10 Page 2 of 6
methods are accredited by Swedac according to ISO
17025 standards.
Statistics
Chi-2 test, independent sample t-test, and Pearson correl-
ation were used for univariate analyses as appropriate. A
multiple logistic regression model was used to differenti-
ate between the effect of the variables age, sex, and birth
year of HSV IgG seroprevalence. To plot HSV seropreva-
lence in relation to age, a linear regression model was used
to fit regression lines.
The HSV incidence was calculated by dividing the num-
ber of new cases with the total follow-up time (person-
years) among HSV negative participants. New cases were
calculated as the number of seroconvertants subtracted by
the number of serorevertants.
P < 0.05 was regarded as statistically significant. The
SPSS 20.0 software for Mac was used for statistical
calculations.
Results
The seroprevalence of IgG antibodies towards five com-
mon human herpes viruses was cross-sectionally investi-
gated in a representative sample (T5 S4) from an adult
Swedish population. The sample included 535 people
(274 women and 261 men) aged 35 to 95 years (mean
age 60.7 ± 16.2 years). The seroprevalence of IgG anti-
bodies against HSV1, HSV2, VZV, CMV and HHV6 are
presented in Table 1.
The relationship between age and sex, and the pres-
ence of herpes virus antibodies was investigated
(Table 2). Women were seropositive for on average 3.8
± 0.7/5 of the analyzed antibodies, compared to 3.6 ±
0.7/5 for men, p = 0.010. Women were more likely to
be HSV2- positive compared to men (p = 0.013). Age
correlated positively with CMV- and HSV1-IgG pres-
ence (p < 0.001 and p < 0.001 respectively), but negatively
with HHV6-IgG presence (p = 0.034). A relationship be-
tween the presence of anti-HSV1 IgG and anti-CMV IgG
was found (Pearson’s r 0.167, p < 0.001), but not between
any other combination.
A larger sample of 3,444 participants from all five co-
horts (S1-5 T1-5) (sampled 1988-2010) was investigated
for HSV IgG seroprevalence with an ELISA developed
in-house. The 535 people in the analyses above were a
subsample of the 3,444. All singular samples and the
first sample from persons that contributed multiple
samples were included. The age ranged between 35 and
95 years, and the mean age was 62.7 ± 14.4. There were
1,860 (54%) women. The anti-HSV IgG seroprevalence
was 3,038/3,444 = 88.2%. In this sample HSV was sig-
nificantly more common among women (1,671 (89.8%)
versus 1,367 men (86.3%), p = 0.001), and the mean age
of HSV positive individuals was higher, when compared
to HSV negative (63.9 ± 14.0 years versus 53.6 ± 14.0 years,
p < 0.001).
In a multiple linear regression model with age and
sex as independent variables, and anti-HSV IgG sero-
positivity as the outcome variable, the calculated in-
crease in anti-HSV seroprevalence for each subsequent
year of age was 0.0051. This value thus corresponds to
0.0051 x 3,444 = 17.6 estimated new cases each year.
The age, sex, and year of birth of the participants were
included in a logistic regression model to individually
investigate the effects of these three variables on the out-
come variable anti-HSV IgG seropositivity (Table 3).
Female sex and earlier year of birth was associated with a
higher anti-HSV IgG prevalence, while increasing age was
not. The birth cohort effect, giving lower age-specific anti-
HSV IgG prevalence in later birth cohorts, is illustrated in
Fig. 1 showing HSV IgG seroprevalence in relation to age
in two temporally separated study cohorts (S1T1: 1988-
1990 and S5T4: 2003-2005).
Samples from 1,231 people who contributed one or
several follow-up sample(s) were included in a longitu-
dinal analysis. These people contributed in total
14,089.83 person-years (PY) of follow-up time, defined
as the timespan from first sample until the last sam-
ple, of which participants who were anti-HSV IgG free
at the beginning of each period contributed 1,289.83
PY follow-up time. During the follow-up period, 28
people seroconverted while 10 people seroreverted,
hence 28 – 10 = 18 was regarded as the number of
incident HSV cases. We treated serorevertants as false
negatives and assumed a similar frequency of false-
positives. HSV incidence was hence calculated as 18/
1,289.83 = 14.0/1000 PY.
In order to discriminate the incidence rate from birth
cohort effects, the calculated incidence, 14.0/1000 PY,
was compared to the figure of yearly increase for the
whole study cohort (17.6).
The 14.0/1000 PY incidence multiplied with 406 anti-
HSV IgG negative participants at baseline would predict
5.7 new anti-HSV IgG positive cases during the forthcom-
ing year. New incident cases hence would account for
Table 1 Herpes virus seroprevalence, N = 535
Virus IgG antibodies Npositive/Ntotal % 95% confidence
interval
Herpes simplex type 1 425/535 79.4 76.0 – 82.9
Herpes simplex type 2 69a/535 12.9 10.1 – 15.8
Varicella zoster virus 524/535 97.9 96.7 – 99.1
Cytomegalovirus 445/535 83.2 80.0 – 86.4
Human herpes virus type 6 517/530b 97.5 96.2 – 98.9
Note: aAmong the 69 HSV2 positive, 50 were HSV1 positive and 16 were
HSV1 negative
bFive samples were unavailable for HHV-6 analysis
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5.7/17.6 = 32.2% of the observed effect of age to anti-
HSV IgG seroprevalence, with the remaining being
the birth cohort effect.
Discussion
We report seroprevalence estimates of five common
human herpes viruses in the general adult population in
Sweden. The most frequent species, VZV and HHV6,
both showed more than 97% prevalence. Studies from
USA report similar figures for VZV (99%) [29]. Even
HHV6 is reported to be prevalent almost ubiquitously in
the adult population [30–33]. We noted a lower preva-
lence for anti-HHV6 antibodies with increasing age, in
line with earlier reports [34, 35]. The prevailing explan-
ation is that the primary infection, and corresponding
humoral immunity, almost exclusively occurs in early
childhood, and that antibody titers decline with age and
thus in some patients goes below our assay’s detection
limit [34]. The seroprevalence for CMV was 83%, con-
firming the high prevalence figures earlier reported from
Sweden, regardless of region studied or urbanization sta-
tus [36–38]. Reports from USA have shown 67%, for a
younger cohort [39, 40] and 87% for a cohort of women
aged 70––79 [41]. Increasing age is associated with in-
creased seroprevalence for CMV, in line with reports of
a significant rate of seroconversion in adults [42]. Sero-
prevalence for HSV1 was 79%, in good agreement with
comparable studies from Switzerland (80%) [43], Sweden
(88%) [44] and Finland (86%) [18]. The HSV2 seropreva-
lence was 13%, placing our cohort in the lower range of
comparable earlier studies from Sweden, (16%) [44], or
USA, (17%) [45]. The prevalence was significantly higher
in women (16%), confirming other cited studies.
Year of birth affected HSV seroprevalence signifi-
cantly. As illustrated in Fig. 1, the age-specific HSV
prevalence is shifted downward in subjects sampled
2003–2005 compared to subjects sampled 1988–1990.
When investigated in a logistic regression model, age
per se had no significant effect on anti-HSV IgG sero-
positivity. This surprising outcome should be inter-
preted in the way that in this study cohort - designed to
allow separation of the two connected variables age and
year of birth - the latter dominates over the former. By
analysis of longitudinal samples, the HSV incidence was
calculated at 14.0/1000 PY in this population and this
incidence rate explains approximately one third of the
increase in prevalence by age. The remaining increase
can be attributed to year of birth differences in the sub-
cohorts, in that later sub-cohorts have a lower preva-
lence. The year of birth differences could be explained
by a decreasing childhood and adolescent risk of HSV,
especially HSV1, infection in the population [46, 47].
Changing lifestyle may also influence HSV spread, given
its routes of transmission. The lack of analysis on the im-
pact of socio-demographic factors such as level of educa-
tion and overcrowding, is a limitation of the present
study. Further studies and the inclusion of younger partic-
ipants would be needed to confirm the observation of a
Table 2 Relationship between presence of Herpes virus IgG antibodies, and age and sex
HSV1 HSV2 VZV CMV HHV6
IgG positivewomen, n (%) 218 (79.6) 45 (16.4) 269 (98.2) 234 (85.4) 266 (98.9)
IgG positivemen, n (%) 207 (79.3) 24 (9.2) 255 (97.7) 211 (80.8) 251 (96.2)
p-value men vs. women 0.943 0.013 0.699 0.159 0.143
AgeIgG positive, mean ± SD 62.9 ± 16.0 61.5 ± 15.3 60.7 ± 16.1 62.2 ± 16.0 60.3 ± 16.1
AgeIgG negative, mean ± SD 52.2 ± 14.0 60.6 ± 16.3 61.3 ± 20.1 53.2 ± 15.4 69.9 ± 12.4
p-value for difference in mean age <0.001 0.638 0.902 <0.001 0.034
Table 3 Multiple binary logistic regression model of HSV positivity,
N= 3,444
Odds ratio 95% confidence interval p-value
Age (years) 1.009 0.989 – 1.030 0.370
Female sex 1.332 1.075 – 1.651 0.009
Year of birth
(four digits)
0.958 0.939 – 0.978 <0.001
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Fig. 1 Linear regression model of anti- HSV IgG seroprevalence in
relation to age in the S1 (solid line) and S5 (double line) cohorts.
Squares mark the mean prevalence in each 5-year age group.
Olsson et al. Immunity & Ageing  (2017) 14:10 Page 4 of 6
decreasing prevalence and could possibly also provide in-
sights on the underlying causes. In light of the accumulat-
ing evidence for a role of HSV1 infection in Alzheimer’s
disease development [3, 5, 6, 48], it is also worth mention-
ing that the incidence of dementia is declining in both
USA and Sweden [49, 50]. Well-designed comparative
studies of age-weighted trajectories will hopefully shed
further light on the impact of HHV infectious burden and
neuronal damage, leading to sequela such as Alzheimer’s
disease.
Conclusion
Prevalence of HSV1 was 79.4%, HSV2 12.9%, CMV 83.2%,
VZV 97.9%, and HHV6 97.5%. Women were more often
found to be seropositive for HHV, especially HSV2. Age-
adjusted seroprevalence for HSV was lower in later birth
cohorts indicating a decreasing childhood and adolescent
risk of infection.
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